Pfizer Inc. ($PFE) Stock Forecast: Down 2.2% Today

What is Pfizer Inc.?

Pfizer (PFE) is a renowned pharmaceutical company known for its wide range of healthcare products, including vaccines, medicines, and consumer healthcare goods. The stock had a bearish movement today amidst recent developments in the pharmaceutical industry.

Why is Pfizer Inc. going down?

PFE stock is down 2.2% on Apr 28, 2026 14:35

• Pfizer's stock experienced a bearish movement possibly due to concerns over its valuation despite recent positive oncology data and FDA Priority Review for its bladder cancer regimen.
• The increase in Pfizer director Susan Desmond-Hellmann's phantom stock units may have raised questions about the company's financial strategies and future outlook, contributing to the downward trend.
• The overall pharmaceutical market sentiment, as reflected in Novartis' strong growth in priority brands and launches, might have overshadowed Pfizer's performance, leading to the bearish movement.
• Investors may be cautious about Pfizer's financial health, considering risks like high debt and potential dividend cuts highlighted by analysts, impacting the stock's downward trajectory.

PFE Price Chart

PFE Technical Analysis

PFE News

Oppenheimer Adjusts Relay Therapeutics Price Target to $18 From $14, Maintains Outperform Rating

Oppenheimer has increased its price target for Relay Therapeutics (RLAY) to $18 from $14, while reiterating an Outperform rating on the stock. This adjustment reflects continued positive sentiment from analysts towards the biotechnology company. The news was reported by MT Newswires.

https://www.marketscreener.com/news/oppenheimer-adjusts-relay-therapeutics-price-target-to-18-from-14-maintains-outperform-rating-ce7f59d2da88fe27

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Novartis reported a strong start to 2026 for its priority brands and launches in Q1, with significant growth in products like Kisqali, Pluvicto, and Kesimpta, although net sales declined due to US generic erosion and increased R&D investment. Despite lower core operating income and EPS, the company reaffirmed its full-year 2026 guidance for low single-digit net sales growth. Novartis also highlighted key R&D milestones, including new approvals, regulatory updates, and positive trial results for several key medicines, alongside strategic acquisitions and corporate transactions.

https://www.globenewswire.com/news-release/2026/04/28/3282207/0/en/novartis-delivered-strong-growth-in-priority-brands-and-launches-in-q1-fy-2026-guidance-reaffirmed.html

Pfizer (PFE) Valuation Check After New Oncology Data And Priority Review For Cancer Regimen

Pfizer (PFE) is under valuation scrutiny after new oncology data and FDA Priority Review for its bladder cancer regimen. Despite recent positive momentum with a 6.39% year-to-date share price return, it trails in longer-term performance. The stock is currently trading at US$26.79, appearing undervalued according to some analysts with a fair value target of $30.62, but carries risks like high debt and potential dividend cuts.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-valuation-check-after-new-oncology-data-and-prior

Pfizer (NYSE: PFE) director awarded 7,686 phantom stock units

Pfizer director Susan Desmond-Hellmann was granted 7,686.539 phantom stock units as part of her deferred board compensation. Each unit is linked to one share of Pfizer common stock, and this award increases her total holdings to 45,635.605 phantom units. These units will be settled in cash or common stock upon her retirement from the board, under Pfizer's Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.

https://www.stocktitan.net/sec-filings/PFE/form-4-pfizer-inc-insider-trading-activity-e0c93f6ac03a.html

Pfizer Inc. (PFE) Files Form 8-K with SEC

Pfizer Inc. (PFE) has filed a Form 8-K with the SEC on April 23, 2026, to provide essential updates and disclosures to investors and stakeholders. These filings typically contain information on financial performance, changes in corporate governance, or other significant corporate events, which are crucial for informed investment decisions in the pharmaceutical industry. GuruFocus.com offers further detailed information and analysis on Pfizer Inc. and its SEC filings.

https://www.gurufocus.com/news/8821419/pfizer-inc-pfe-files-form-8k-with-sec

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.9% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 15.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.5% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 6.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 23.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 9.5% Today

Internationa Flavors & Fragrances Inc. ($IFF) Stock Forecast: Up 17.2% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 6.0% Today

Devon Energy Corporation ($DVN) Stock Forecast: Down 8.6% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Up 6.3% Today

Pfizer Inc. Price History

04.10.2025 - PFE Stock was up 0.2%

• Pfizer's stock showed strong bullish movement today after surpassing earnings and revenue estimates for the third quarter of 2025, displaying robust financial performance.
• The market responded positively to Pfizer increasing its profit guidance despite a slight decline in sales, reflecting investor confidence in the company's ability to overcome obstacles and sustain profitability.
• The updated proposal from Novo Nordisk to acquire Metsera might have influenced market sentiment, potentially bolstering Pfizer's position in the pharmaceutical sector as competitors seek strategic acquisitions.
• Overall, Pfizer's strong performance in core drug sales and positive profit outlook in a challenging market environment likely contributed to the bullish movement in its stock price today.

16.11.2025 - PFE Stock was down 5.1%

• The bearish movement in Pfizer's stock today could be attributed to profit-taking by investors after a recent bullish run or concerns about competition in the pharmaceutical sector.
• The call-put ratio for Cintas Corp. (CTAS) and the positive outlook on Microsoft Corporation (MSFT) and Regeneron Pharmaceuticals, Inc. (REGN) might have diverted investor attention away from Pfizer.
• Institutional accumulation in Sealed Air Corporation (SEE) and AbbVie Inc. (ABBV) could have signaled more attractive investment opportunities compared to Pfizer, leading to the bearish movement in its stock.
• Overall, Pfizer's bearish movement today may be a short-term market correction influenced by broader market trends and investor sentiment towards other pharmaceutical companies.

16.11.2025 - PFE Stock was down 4.4%

• Pfizer's bearish movement today is linked to the company's projection of lower profits in 2026 due to an expected decrease in COVID product sales and revenue loss from drugs losing exclusivity. This information likely sparked concerns among investors regarding the company's future earnings.
• Despite confirming its 2025 earnings guidance, Pfizer's updated revenue forecast slightly below Street expectations potentially let down investors, resulting in a sell-off of the stock.
• The institutional accumulation trend in other pharmaceutical companies like Regeneron Pharmaceuticals and AbbVie, accompanied by analyst upgrades and positive earnings, may have diverted investor focus from Pfizer, contributing to the downward movement in its stock price today.
• Shorepoint Capital Partners LLC's investment in Pfizer, coupled with adjustments in holdings by other institutional investors, demonstrates sustained interest in the company despite the profit projection and revenue worries, hinting at a possible stock rebound in the future.

10.10.2025 - PFE Stock was down 2.2%

• The bearish movement in Pfizer's stock could be attributed to the uncertainty surrounding the fierce bidding war with Novo Nordisk over the acquisition of Metsera, Inc., a significant deal worth $10 billion. The market might be reacting negatively to the potential financial implications and risks associated with this high-stakes competition.
• Additionally, Trump's Most Favored Nation (MFN) policy aimed at reducing U.S. drug prices could be adding pressure on Pfizer and other pharmaceutical companies, leading to concerns about future revenue streams and profitability.
• The court's decision to deny Pfizer's request for a temporary restraining order to block Novo Nordisk's bid for Metsera might have further fueled investor uncertainty and contributed to the bearish sentiment surrounding Pfizer's stock.
• Overall, the combination of the bidding war, drug pricing concerns, and legal setbacks could have collectively influenced the bearish market movement for Pfizer today. Investors are likely closely monitoring the developments in these ongoing battles and policy changes to assess the company's future performance.

24.03.2026 - PFE Stock was up 2.8%

• Pfizer's collaboration with Bristol Myers Squibb and Mark Cuban Cost Plus Drug Company to make Eliquis more affordable and accessible for cash-paying patients has positively impacted investor sentiment.
• The positive Phase 2b results for Pfizer's once-monthly GLP-1 anti-obesity candidate have signaled a significant expansion of its obesity pipeline, attracting investor interest in the company's future growth potential.
• These strategic moves by Pfizer to address access barriers for important medications and expand its product pipeline have likely contributed to the bullish movement in the stock price today.

28.03.2026 - PFE Stock was down 2.2%

• Pfizer's stock experienced a bearish movement possibly due to concerns over its valuation despite recent positive oncology data and FDA Priority Review for its bladder cancer regimen.
• The increase in Pfizer director Susan Desmond-Hellmann's phantom stock units may have raised questions about the company's financial strategies and future outlook, contributing to the downward trend.
• The overall pharmaceutical market sentiment, as reflected in Novartis' strong growth in priority brands and launches, might have overshadowed Pfizer's performance, leading to the bearish movement.
• Investors may be cautious about Pfizer's financial health, considering risks like high debt and potential dividend cuts highlighted by analysts, impacting the stock's downward trajectory.

06.00.2026 - PFE Stock was up 2.5%

• Pfizer announced a strategic collaboration with Cartography Biosciences to discover tumor-selective antigens, possibly boosting investor confidence in the company's future growth prospects.
• The increase in stake by Torray Investment Partners LLC indicates a positive sentiment towards Pfizer's stock, contributing to the bullish movement.
• The positive results announced by Alumis for its psoriasis pill may have indirectly impacted Pfizer's stock, as it highlights advancements in the pharmaceutical industry, including potential future collaborations and developments.
• Despite Gateway Investment Advisers LLC lowering its stock position in Pfizer, the overall increase in stake by other institutional investors and the company's strong Q3 performance likely outweighed this negative news, driving the bullish movement.